Mindbio Therapeutics CEO Issues Letter To Shareholders
Mindbio Therapeutics CEO Issues Letter To Shareholders
Mindbio治療公司CEO向股東發出信函
Dear Shareholders,
親愛的股東：
We are delighted to provide an update on progress at MindBio, as we head into the second half of 2024 and continue with dosing in multiple Phase 2B clinical trials and we advance the Company closer towards its commercialisation objective.
很高興向大家通報MindBio的進展情況。我們將進入2024年的下半年，並繼續在多項第20億期臨床試驗中進行劑量測定，使公司更加接近商業化目標。
The Company is pleased to report on its two currently dosing Phase 2B clinical trials which include assessing MB22001, MindBio's lead candidate drug in treating the following conditions:
公司很高興地報告其目前正在劑量的兩個第20億期臨床試驗，這些試驗包括評估MB22001，MindBio在治療以下疾病方面的首選藥物：
MindBio Leads Global Public Companies in Non-hallucinogenic Psychedelic Clinical Trials
MindBio在非致幻性迷幻臨床試驗中領先全球上市公司
MindBio is the only publicly listed company in the world specializing in a scalable psychedelic microdosing treatment model that is sub-hallucinogenic...
MindBio是全球唯一一家專門從事可擴展迷...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。